Developing delta opioid receptor agonists for migraine treatment

Amynah Pradhan, PhD, Washington University in St. Louis, St. Louis, MO, discusses potential explanations for the lack of success seen to date in the development of treatments targeting δ-opioid receptors (DORs). One theory is that DOR agonists are not effective at targeted at peripheral pain states, which has been the focus research so far, and would be more effective if targeted at migraine. Dr Pradhan also highlights questions about the efficacy of the compounds themselves. Notably, the use of DOR agonists has not resulted in any severe adverse events across the trials. She concludes that the next steps may be to find the right chemical compound for the treatment of the right condition. This interview took place at the American Headache Society (AHS) Annual Meeting 2024 in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.